Overview

* Curis ( CRIS ) Q3 revenue increased year-over-year, beating analysts' expectations of a decline

* Net loss for Q3 narrowed to $7.13 mln from $10.1 mln

* Company continues advancing clinical studies in PCNSL, CLL, and AML

Outlook

* Curis expects to enroll first CLL patient in late Q4 2025 or early Q1 2026

* Company anticipates cash runway into Q1 2026

Result Drivers

* ROYALTY REVENUE - Revenue rose to $3.2 mln from $2.9 mln, consisting of royalty revenues from Genentech/Roche's sales of Erivedge

* R&D EXPENSES - Declined to $6.4 mln from $9.7 mln due to lower clinical, employee related, manufacturing, research, and consulting costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $3.18 $2.86

Revenue mln mln (5

Analysts

)

Q3 Net Beat -$7.73 -$8.22

Income mln mln (5

Analysts

)

Q3 Basic Beat -$0.49 -$0.58

EPS (5

Analysts

)

Q3 Beat -$6.92 -$8.20

Income mln mln (4

From Analysts

Operatio )

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Curis Inc ( CRIS ) is $17.00, about 91.6% above its November 5 closing price of $1.42

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)